NervGen Pharma Corp (NGEN : TSX-V)
Common Stock
Follow NGEN
NGEN
NervGen Pharma Corp
WealthAwesomePerformance
1 Day
+0.00%
1 Week
+0.00%
1 Month
+0.00%
YTD
-35.06%
The Tuesday Stock Pick · free, every tuesday morning. One Canadian stock and the case for it.
Key Statistics
Market Cap
$407.94M
52W High
$8.49
52W Low
$2.57
P/E Ratio
-
50 Day MA
$6.19
200 Day MA
$4.60
Beta
0.86
Dividend Yield
-
WA Score
How NGEN stacks up against 947 Canadian stocks
29
out of 99
- Value27
Not profitable over the last 12 months.
- Quality2
Return on equity −820.1%.
- Momentum51
−35.1% this year, above its 200-day average, 44% of the way up its 52-week range.
- Analysts66
Average analyst target is 45.3% above the price.
- Insiders71
4 open-market buys and 0 sales on SEDI in 180 days (net $37K).
Each factor is a percentile against Canadian common stocks worth $50M or more on the TSX and TSX Venture (90 = better than 90% of them). Built from exchange prices, company financials, analyst targets and SEDI insider filings. A data summary, not advice. How it works · Top-scoring stocks
Performance history
NGEN returns since 2023
NervGen Pharma Corp has traded since Nov 2023 in our data, with 2 up years out of 2 full calendar years. Its deepest fall was −57.5% (May 2025 to Aug 2025).
1 year / yr
+87.3%
3 years / yr
—
5 years / yr
—
10 years / yr
—
Calendar-year returns
- 2023*+50.0%
- 2024+16.3%
- 2025+144.6%
- 2026*−32.9%
* Partial year (first year of data, or year to date).
$10,000 invested in NGEN
- 1 year ago$18,727
- 2023 (start of our data)$28,611
- Best year
- 2025: +144.6%
- Worst year
- 2024: +16.3%
- All-time high in our data
- $8 on Jan 8, 2026 · now −36.3%
Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Nov 2023 to Mar 2026. Past returns do not predict future ones.
Awesome Portfolio™
Looking past NGEN? Our 10 best Canadian stocks, in one list.
14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.
NervGen Pharma Corp insider transactions
Open-market and private equity trades (last 12 months volume). Derivatives and opening balances excluded.
Recent transactions
| Date | Side | Name | Shares | Price |
|---|---|---|---|---|
| Jul 28, 26 | Buy | Ruffolo, John Individual · CA$328 | 200 | CA$1.64 |
| May 27, 26 | Buy | Ruffolo, John Individual · CA$33 | 16 | CA$2.08 |
| May 27, 26 | Buy | Ruffolo, John Individual · CA$18,234 | 8,775 | CA$2.08 |
| May 27, 26 | Buy | Ruffolo, John Individual · CA$18,234 | 8,775 | CA$2.08 |
| May 26, 26 | Buy | Rogers, Adam Individual · CA$2.0m | 800,000 | CA$2.50 |
| May 26, 26 | Buy | Rogers, Adam Individual · CA$2.9m | 800,000 | CA$3.68 |
| Apr 29, 26 | Buy | Punnett, Harold Individual · CA$15,912 | 4,250 | CA$3.74 |
| Apr 08, 26 | Sell | McKerracher, Krista Individual · CA$41,914 | 10,000 | CA$4.19 |
| Apr 02, 26 | Sell | McKerracher, Krista Individual · CA$21,150 | 5,000 | CA$4.23 |
| Mar 09, 26 | Sell | McKerracher, Krista Individual · CA$19,924 | 5,000 | CA$3.98 |
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 3/17/2026 | $5.15 | $5.15 | $5.15 | $5.15 | $5.15 | 0 |
| 3/16/2026 | $4.95 | $5.23 | $4.93 | $5.15 | $5.15 | 66,939 |
| 3/13/2026 | $5.20 | $5.30 | $4.87 | $5.00 | $5.00 | 114,157 |
| 3/12/2026 | $5.34 | $5.38 | $5.20 | $5.26 | $5.26 | 37,210 |
| 3/11/2026 | $5.50 | $5.50 | $5.29 | $5.35 | $5.35 | 42,945 |
| 3/10/2026 | $5.55 | $5.70 | $5.45 | $5.50 | $5.50 | 34,365 |
| 3/9/2026 | $5.46 | $5.63 | $5.35 | $5.61 | $5.61 | 35,823 |
| 3/6/2026 | $5.50 | $5.56 | $5.42 | $5.46 | $5.46 | 32,955 |
| 3/5/2026 | $5.85 | $5.85 | $5.45 | $5.53 | $5.53 | 67,514 |
| 3/4/2026 | $5.45 | $5.93 | $5.45 | $5.89 | $5.89 | 40,846 |
Analyst Price Targets
Based on analyst covering NGEN · as of Sep 17, 2026
Wall Street analysts forecast NGEN stock price to rise 436.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.48
+436.4% Upside
Current Price
C$1.40
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on NGEN's historical volatility
30-Day Vol
61.5%
Annualized
90-Day Vol
82.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$4.31
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$4.85 | C$3.92 – C$6.00 |
| 60 trading days | C$4.57 | C$3.39 – C$6.17 |
| 90 trading days | C$4.31 | C$2.98 – C$6.22 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About NervGen Pharma Corp
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-25.20M
- Profit Margin
- 0.00%
- ROE (TTM)
- -820.11%
- EPS (Diluted)
- -0.36
- Book Value
- -0.04
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Free newsletter
The Tuesday Stock Pick
One Canadian stock and the case for it
- The name with the biggest gap to analyst targets
- The chart, insider buying and what is driving it
- A plain-English bottom line, no hype
Explore More
Common Questions About NGEN
Market movers
Recent TSX-V movers
Top 1-day gainers — updated from our Canadian movers feed.